By eCliniqua Staff  

May 4, 2012 | Quanticate is expanding its contract research capabilities for clinical trials in India with the announcement of a new office in Bangalore. The new office will take further advantage of growing clinical trials opportunities in India.      

“Expansion of our facility in India is in direct response to the requirements of our customers and the driving force that enabled us to significantly grow in this region,” explained Daniel Chapple, EVP and chief commercial officer in a press release.   

Quanticate is primarily focused on the management, analysis and reporting of data from clinical trials and post-marketing surveillance. India has become known as a lower cost location for clinical trials, however it presents challenges in terms of account oversight, communication, and quality control at both the CRO and customer side.   

Karen Oooms, EVP of operations (Strategic Delivery) said that these quality issues are ones Quanticate is particularly invested in addressing. “Quanticate has been careful in its approach to using lower cost regions and does so for more than the purpose of achieving more attractive labor rates.  The employees that are working in all our sites are not only highly experienced but also have a focus on teamwork to ensure that the high quality deliverables and communication that Quanticate has a reputation for is not impacted.”  

Chapple added: “Research has shown that customers turn to Quanticate because of our experience, knowledge and the high quality that we offer.  Now through this expansion, our customers will also benefit from even more cost effective offerings, particularly with the large-scale FSP’s that we have in place.”  

This is a season of growth for Quanticate, Ooms said. “We anticipate that all our locations will continue to grow based upon our healthy pipeline. This is an exciting time at Quanticate as we have recently launched our centralized data solution and we have been adding new expertise and technologies to support both our customers and our growing number of highly skilled statisticians, programmers, data managers, medical writers and pharmacovigilance experts.”